FMD K&L is a global contract research organization supporting data management, biostatistics, statistical programming, clinical operations, regulatory affairs, safety, pharmacovigilance, toxicology, medical affairs, medical writing, quality, risk, and compliance services to the pharmaceutical, biotechnology, and medical device industries worldwide. We continuously strive to raise the standard of excellence through accuracy and efficiency to achieve the highest quality output for our partners. K&L was established in the US in 1995, and has grown to more than 1,400 employees worldwide, with key offices and delivery centers in the US, UK, China, India, Armenia, Japan and throughout the Asia-Pacific region.
Click above on Services to explore our broad capabilities and offerings.
FMD has successfully hosted a webinar titled “Leverage the Favorable Regulatory Reforms in China to Accelerate Global Drug Development Programs“. Dr. Dan Zhang, Executive Chairman of FMD, and Emil Fu, SVP International Integration of FMD, discussed the regulatory reform in China and the strategies biopharma companies can take to make your programs more efficient.
This whitepaper highlights the key EU MDR regulatory changes with what organizations may need to know to ensure they are prepared and compliant with these regulations.
Follow FMD K&L on LinkedIn for the latest on global product development. Read breaking stories, editorials by key opinion leaders, and articles by and/or about FMD K&L.